

Press release  
October 30, 2007  
Kungsbäcka, Sweden

## Approval for fertility media in Australia

**As one of the first companies outside Australia, Vitrolife has received sales approval from the Australian Medical Products Agency, TGA, for its fertility media. This registration approval means that Vitrolife can now market its products to all clinics on the same terms as local suppliers. TGA has after review also issued a certificate regarding Vitrolife's quality system.**

"The market in Australia is important as it is an opinion leader in large parts of Asia and can form a bridgehead for continued expansion in the Asia/Pacific region, which today has the fastest growth", says Nils Sellbom, Vitrolife's Sales Director. "We also see that a great deal of pioneering research within IVF and stem cells originates in clinics and universities in Australia."

The Australian Medical Products Agency TGA has also issued a so-called "Conformity Assessment Certificate" for Vitrolife's plant in Kungsbäcka. The certificate is based on an extensive examination of the business, and recognition means that Vitrolife has a full quality management system applied from the design until final inspection of the ready medical device.

October 30, 2007  
Kungsbäcka, Sweden

Magnus Nilsson  
CEO

**Queries should be addressed to:**

Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.  
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company's products are sold in more than 80 markets. The head office is in Kungsbäcka, Sweden, and there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbäcka, Sweden. Corporate identity number 556354-3452.  
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Homepage: [www.vitrolife.com](http://www.vitrolife.com).

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.